Hecht J Randolph, Blanke Charles D, Benson Al B, Lenz Heinz J
UCLA School of Medicine, Los Angeles, California, USA.
Oncology (Williston Park). 2003 Sep;17(9 Suppl 8):13-5.
Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.
伊立替康（CPT-11，开普拓）和紫杉醇在食管腺癌和贲门腺癌中均显示出单药活性。加州大学洛杉矶分校进行的一项该联合方案的I期试验确定剂量为伊立替康225mg/m²，紫杉醇100mg/m²，每3周一次。该方案在胃食管交界腺癌的II期试验的初步数据显示，即使是先前接受过治疗的患者，耐受性良好且活性可观（缓解率为27%）。
